Search Results - generate

3 Results Sort By:
Floxed Targeted Mouse Strain for Use in Conditional Deletion of the Irf8 Gene
IRF8, a member of interferon regulatory factor (IRF) family of transcription factors is a novel intrinsic transcriptional inhibitor of TH17-cell differentiation. TH17-cells are believed to be involved in the pathogenesis of various autoimmune/inflammatory diseases. These materials could be used to help define patterns of gene expression important for...
Published: 10/28/2024   |   Inventor(s): Herbert Morse
Keywords(s): Approved, Conditional, Deletion, Design, Development, Gene, Generate, IRF8, Knockout, Listed LPM Vepa as of 4/15/2015, Mouse, Need, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECOGNIZED, RXXXXX, Strain, Used
Category(s): Collaboration Sought > Collaboration, Application > Research Materials
Cell Based Immunotherapy
The invention hereby offered for licensing is in the field of Immunotherapy and more specifically in therapy of autoimmune diseases such as Type I diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosis and immune mediated allergies such as asthma as well as in transplantation-related disorders, such as graft acceptance...
Published: 10/28/2024   |   Inventor(s): Ethan Shevach, Dat Tran
Keywords(s): 2, ACTIVATED, ALLOWS, Aplastic anemia, Aplastic anemia, idiopathic; Aplastic anemia, Associated, CD121b, CELL-BASED, Cells, CULTURES, EXPANSION, Expression, FOXP3+, Generate, Graft versus host disease, Human, IB3XXX, IBXXXX, Idiopathic thrombocytopenic purpura, IL-l, Immunotherapy, IXXXXX, LAP, Latency, NUMBERS, Patent Category - Biotechnology, Peptide, purification, RECEPTOR, Regulatory, SELECTIVE, Sufficient, Systemic lupus erythematosus, T, Their, Thrombocytopenic purpura, autoimmune, TYPE
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials
Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines
The identified technologies describe self-replicating infectious recombinant paramyxoviruses with one or more attenuating mutations, such as a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein, or at least one temperature sensitive mutation and one non-temperature sensitive mutation....
Published: 10/28/2024   |   Inventor(s): Peter Collins, Sheila Nolan, Mario Skiadopoulos, Brian Murphy
Keywords(s): cDNA, CIS-ACTING, Complete, DC5BXX, DC5XXX, DCXXXX, Determination, DXXXXX, FOR..., FRAMES, Gene, Generate, Generation, Genomic, HPIV2, HPIV2., HPIV2/V94, Identification, MEASLES, Mumps, MUTATION, Novel, Nucleotide, Overlapping, P/V, Parainfluenza virus type 3, Parainfluenza virus type 3; Human parainfluenza virus type 3, Reading, recombinant, rHPIV2, Separated, sequence, Strain, UA1XXX, USEFUL, V94
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines, TherapeuticArea > Infectious Disease